RXi received patent rights from The Henry M. Jackson foundation to develop and commercialize NeuVax for use in combination with Herceptin trastuzumab

The Henry M. Jackson Foundation

U.S. / Non-Profit or Major Disease Foundation

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

RXi Pharmaceuticals Corp.

U.S. / Small-Cap Biopharma (<$1 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced